Testing new antimicrobial agents called darobactins
Evaluating darobactins as antimicrobial agents
['FUNDING_R01'] · NORTHEASTERN UNIVERSITY · NIH-11054679
This study is looking at a new type of medicine called darobactins to see how well it can fight tough infections caused by bacteria that don't respond to many other treatments, and it's for anyone who is dealing with these hard-to-treat infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHEASTERN UNIVERSITY (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11054679 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of darobactins, a novel class of antimicrobial agents, against multidrug-resistant Gram-negative bacteria. The study focuses on how these compounds interact with a specific protein, BamA, which is crucial for bacterial survival. By understanding the binding mechanism of darobactins, researchers aim to develop new treatments for infections caused by resistant bacteria. The research involves laboratory experiments and animal models to assess the safety and efficacy of these agents.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by multidrug-resistant Gram-negative bacteria.
Not a fit: Patients with infections caused by antibiotic-sensitive bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for infections caused by antibiotic-resistant bacteria, improving patient outcomes.
How similar studies have performed: Other research has shown promise in developing new antimicrobial agents targeting similar mechanisms, indicating potential for success in this area.
Where this research is happening
BOSTON, UNITED STATES
- NORTHEASTERN UNIVERSITY — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEWIS, KIM — NORTHEASTERN UNIVERSITY
- Study coordinator: LEWIS, KIM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.